Taysha Gene Therapies (NASDAQ:TSHA) Upgraded to “Hold” at Wall Street Zen

Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Several other equities research analysts have also commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, September 21st. The Goldman Sachs Group lifted their target price on Taysha Gene Therapies from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Finally, Wolfe Research began coverage on Taysha Gene Therapies in a report on Thursday, September 17th. They set an “outperform” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $12.75.

Taysha Gene Therapies Stock Down 2.6%

Shares of TSHA stock opened at $4.10 on Friday. Taysha Gene Therapies has a 12 month low of $3.45 and a 12 month high of $7.30. The stock has a market cap of $1.34 billion, a P/E ratio of -9.53 and a beta of 1.36. The company has a current ratio of 17.76, a quick ratio of 17.76 and a debt-to-equity ratio of 0.13. The company has a 50 day simple moving average of $4.49 and a two-hundred day simple moving average of $5.28.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.03. On average, research analysts expect that Taysha Gene Therapies will post -0.52 earnings per share for the current year.

Institutional Trading of Taysha Gene Therapies

Hedge funds and other institutional investors have recently modified their holdings of the company. First Trust Advisors LP raised its position in shares of Taysha Gene Therapies by 47.8% during the 3rd quarter. First Trust Advisors LP now owns 1,169,158 shares of the company’s stock valued at $5,694,000 after purchasing an additional 377,989 shares during the period. Voya Investment Management LLC lifted its stake in shares of Taysha Gene Therapies by 10.4% during the 3rd quarter. Voya Investment Management LLC now owns 469,808 shares of the company’s stock valued at $2,288,000 after buying an additional 44,445 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Taysha Gene Therapies by 21.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 75,147 shares of the company’s stock valued at $366,000 after buying an additional 13,442 shares in the last quarter. Ethic Inc. boosted its holdings in Taysha Gene Therapies by 117.2% in the 3rd quarter. Ethic Inc. now owns 27,182 shares of the company’s stock worth $132,000 after buying an additional 14,670 shares during the period. Finally, Pictet Asset Management Holding SA boosted its holdings in Taysha Gene Therapies by 19.6% in the 3rd quarter. Pictet Asset Management Holding SA now owns 3,313,062 shares of the company’s stock worth $16,135,000 after buying an additional 542,361 shares during the period. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies is a biotechnology company focused on developing gene therapies for rare, genetically driven diseases. Based in Dallas, Texas, the company was founded in 2019 and has built its programs around adeno-associated virus delivery technology. The company’s lead program, TSHA-102, is an investigational gene therapy being developed for Rett syndrome, a rare neurological disorder. Taysha’s research has also included gene therapy programs for other rare diseases, including giant axonal neuropathy.